Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $135 from $122 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 sales in line with the January preannouncement and reiterated 2026 guidance. Wells believes management sees Epioxa volume ramping back to Photrexa peak by 2030, implying over $1B opportunity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: